This article is a correction to:
Effects of Vitamin D and K on Interleukin-6 in COVID-19
Margot P. J. Visser1†
Anton S. M. Dofferhoff2†
Jody M. W. van den Ouweland3Henny van Daal3
Cornelis Kramers4
Leon J. Schurgers5Rob Janssen1†Jona Walk2*†- 1Department of Pulmonary Medicine, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands
- 2Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands
- 3Department of Clinical Chemistry, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands
- 4Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
- 5Department of Biochemistry, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands
A Corrigendum on
Effects of Vitamin D and K on Interleukin-6 in COVID-19
by Visser, M. P. J., Dofferhoff, A. S. M., van den Ouweland, J. M. W., van Daal, H., Kramers, C., Schurgers, L. J., Janssen, R., and Walk, J. (2022). Front. Nutr. 8:761191. doi: 10.3389/fnut.2021.761191
In the original article, there was a mistake in Figure 4 as published. The </> signs were accidentally switched in the figure. The corrected Figure 4 appears below.
FIGURE 4
Figure 4. The association between the differences in vitamin K status /vitamin D status /desmosine and IL-6 levels in COVID-19 patients. Vitamin K levels were defined as “low” when dp-ucMGP levels were above median, and “high” when dp-ucMGP levels were below median. Vitamin D levels were defined as “low” when there was a 25(OH)D insufficiency (concentration < 50 nmol/L) and “high” when there was a sufficient amount of vitamin D (concentration > 50 nmol/L). (A) The effect of vitamin K status — derived from dp-ucMGP status — on desmosine levels in patients with high or low vitamin D levels. Desmosine levels were measured in 122 patients. (B) The effect of vitamin K status — derived from dp-ucMGP status — on IL-6 levels in patients with high or low vitamin D levels (n = 131). *Indicates significant difference between groups.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: COVID-19, desmosine, dp-ucMGP, vitamin D, vitamin K, IL-6, 25-hydroxyvitamin D
Citation: Visser MPJ, Dofferhoff ASM, van den Ouweland JMW, van Daal H, Kramers C, Schurgers LJ, Janssen R and Walk J (2022) Corrigendum: Effects of Vitamin D and K on Interleukin-6 in COVID-19. Front. Nutr. 9:868324. doi: 10.3389/fnut.2022.868324
Received: 02 February 2022; Accepted: 09 February 2022;
Published: 08 March 2022.
Edited and reviewed by: Stefanos Roumeliotis, University General Hospital of Thessaloniki AHEPA, Greece
Copyright © 2022 Visser, Dofferhoff, van den Ouweland, van Daal, Kramers, Schurgers, Janssen and Walk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jona Walk, jona.walk@cwz.nl
†These authors have contributed equally to this work